Scientific Foundation
Hydrogen Sulfide – The Next-Generation Gaseous Mediator
Since the early 1980s, gaseous mediators* have been recognized as important regulators in physiological and pathological processes in humans. These discoveries were recognized in the award of the Nobel Prize for Medicine in 1998. (One of the recipients of this Nobel Prize, Dr. Louis Ignarro, is a member of Antibe’s Board of Directors.)
Antibe’s scientists have been at the forefront of research into the therapeutic value of gaseous mediators. In their opinion, hydrogen sulfide’s therapeutic value shows particular promise, and is now beginning to be recognized by the wider scientific and medical communities.
Hydrogen sulfide is a vasodilator, analgesic and anti-inflammatory, and has important immunomodulatory properties.
Antibe pairs a hydrogen sulfide releasing moiety with already proven, off-patent drugs utilized in diseases characterized by inflammation, vascular dysfunction and pain. This yields a new drug, with corresponding new patent protection, yet retaining the benefits of clinician, regulatory and physician familiarity, as well as a significant reduction in development risk.
The Company expects to begin human clinical trials of ATB-429, its lead drug, in Q4/2008.